An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Palliare Announces EU CE Mark Approval Under New Medical Devices Regulation
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Palliare Signs first US GPO Agreement
Positive
None.
Negative
None.
Palliare Signs first US GPO Agreement
GALWAY, Ireland & OCEANSIDE, Calif.--(BUSINESS WIRE)--
Palliare, a leading developer of advanced insufflation technologies, has received EU CE Mark certification under the new EU Medical Devices Regulation (MDR) for its EVA15 insufflator and smoke evacuation system. This makes it one of the first laparoscopic and endoscopic insufflators to meet the new more extensive regulatory requirements introduced in 2021 for medical devices in Europe and will now permit the company to commence shipments to the European market with immediate effect.
John O'Dea, Caroline O'Dea from Palliare being presented with EVA15 Certification certificates by Kevin Mullaney, Director of Certification, NSAI (Photo: Business Wire)
Commenting on the clearance, John O’Dea, CEO, said “We believe that this is an important step forward for our company. Certifying EVA15 as a Class 2b device to the new MDR regulation has entailed an extensive exercise, one that puts the company on a firm regulatory approval footing in Europe for the coming years. We have now started the process of installing EVA15 in leading robotic surgical training centers in Europe.”
NSAI CEO, Geraldine Larkin, continued “Certification is a key pillar for companies in the medical devices sector to drive innovation, ensure quality, and to gain market accessibility. Ireland is a major hub for the medical devices sector in Europe and the ability of the NSAI to certify products for access to the European market is an important part of our work in supporting Irish business.”
In further news, Palliare is pleased to announce that it has signed a GPO agreement with Northwell Health, New York's largest healthcare provider. Palliare engaged with Northwell’s Global Strategic Partnerships team and came through their International Business Program, an established program for international companies to work with the Northwell system. Elaine Brennan, Executive Director of Global Strategic Partnerships said, “We created this program to streamline engagement with international companies that add value for Northwell – from procurement to pilots to investment opportunities – and we’re glad to add Palliare as a solution for Northwell and partner within the GPO alliance.”
Commenting, David Corcoran, Head of US LifeSciences, Enterprise Ireland said “Palliare's innovative smoke evacuation and insufflation technologies are transforming surgical operating rooms, addressing the growing demands of patient procedures while also enhancing safety. Enterprise Ireland proudly supports Palliare's US scaling journey, and are delighted that Palliare and Northwell Health, a longstanding strategic partner of Enterprise Ireland and leading US healthcare system, have collaborated to accelerate the adoption of these transformative technologies, driving improved patient outcomes.”
About the EVA15 Insufflator
The EVA15 insufflator and smoke evacuation system is the first product from Palliare, designed to create a safer operating room environment and deliver best-in-class insufflation and smoke evacuation performance to meet the particular demands of laparoscopic, endoluminal, endoscopic, and robotic surgical procedures. EVA15 is currently cleared by the US FDA for sale in the USA, and is now CE marked in Europe and offers similar smoke evacuation and insufflation performance to the Conmed (NYSE: CNMD) Airseal system.
About Palliare
Palliare was founded in 2018 as a spinout from Irish gastro-diagnostic company Crospon, which was acquired by Medtronic (NYSE:MDT) in 2017. Based in Galway, Ireland, and with US headquarters in Oceanside, CA, Palliare is dedicated to advancing the state of the art in smoke evacuation and insufflation technologies for laparoscopic, endoluminal, endoscopic, and robotic surgery. For more information about Palliare, visit www.palliare.com.
What is the significance of Palliare receiving EU CE Mark certification for its EVA15 insufflator and smoke evacuation system?
Palliare's EVA15 insufflator is one of the first laparoscopic and endoscopic insufflators to meet the new, more extensive regulatory requirements introduced in 2021 for medical devices in Europe, allowing the company to commence shipments to the European market immediately.
What is the importance of Palliare signing a GPO agreement with Northwell Health?
The GPO agreement with Northwell Health, New York's largest healthcare provider, allows Palliare to streamline engagement with international companies and collaborate with Northwell within the GPO alliance, enhancing market accessibility and driving improved patient outcomes.
How does Palliare's collaboration with Northwell Health impact the adoption of its innovative technologies?
Palliare's collaboration with Northwell Health accelerates the adoption of its transformative smoke evacuation and insufflation technologies, addressing the growing demands of patient procedures and enhancing safety in surgical operating rooms.
